Trial Profile
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Romidepsin (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Therapeutic Use
- 29 Jun 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 18 Oct 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2023.